Abstracts tagged "uric acid"

Abstract Number: 338 • 2019 ACR/ARP Annual Meeting
Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults
Angelo Gaffo¹, David Calhoun ², Elizabeth Rahn ¹, Suzanne Oparil ², Peng Li ², Tanja Dudenbostel ², David Redden ², Amy Mudano ², Jeffrey Foster ¹, Daniel Feig ², Stephanie Biggers ² and Kenneth Saag ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: The association between serum urate and hypertension continues to be a matter of controversy. Studies in adolescents provided evidence for the efficacy of urate…
Abstract Number: 357 • 2019 ACR/ARP Annual Meeting
Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification
Andrew Shaffer¹, Elizabeth Rahn ², Kenneth Saag ², Amy Mudano ³ and Angelo Gaffo ², ¹University of Alabama at Birmingham, Vestavia, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham
Background/Purpose: Previous studies have noted significant variation in serum urate (sUA) levels, and it is unknown how this influences the accuracy of hyperuricemia classification based…
Abstract Number: 1224 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
Rongzi Yan¹, Nanqun Zhu ², zancong shen ³, Shunqi Yan ⁴ and Litain Yeh ¹, ¹Arthrosi Therapeutics, Laguna Hills, ²Consultant, Laguna Hills, CA, ³Arthrosi Therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics. Inc, Laguna Hills, CA
Background/Purpose: AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which is responsible for a majority of reabsorption of filtered uric…
Abstract Number: 1234 • 2019 ACR/ARP Annual Meeting
Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?
Brittany Frankel¹, Grant Hughes ¹ and Mark Wener ¹, ¹University of Washington, Seattle, WA
Background/Purpose: Elevated serum uric acid (UA) concentration is associated with the urate crystal deposition disorders gout and nephrolithiasis, as well as hypertension, the metabolic syndrome,…
Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
John A. Albert¹, Tony Hosey ² and Brian LaMoreaux ², ¹Rheumatic Disease Center, Milwaukee, IL, ²Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…
Abstract Number: 2073 • 2019 ACR/ARP Annual Meeting
The Association of Serum Uric Acid Levels and the Risk of Lower Urinary Tract Symptoms in Korean Healthy Adults
Jiwon Hwang¹, Seung-ho Ryu ² and Joong Kyong Ahn ³, ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, Republic of Korea, ²Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Along the aging process, men frequently appeal lower urinary tract symptoms (LUTS). The impact of LUTS on quality of life and mental health was apparent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].